Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

GENE THERAPY

Surrogate gene therapy for muscular dystrophy

Nature Medicine volume 25, pages 1473–1474 (2019)Cite this article

Subjects

An engineered truncated gene derived from the dystrophin-related protein (utrophin), prevents pathology without an immune response in an animal model of Duchenne muscular dystrophy (DMD) gene therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Utrophin gene therapy for DMD.

References

  1. Guiraud, S. et al. The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genomics Hum. Genet. 16, 281–308 (2015).

    Article  CAS  Google Scholar 

  2. Song, Y. et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat. Med. https://doi.org/10.1038/s41591-019-0594-0 (2019).

  3. Duan, D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol. Ther. 26, 2337–2356 (2018).

    Article  CAS  Google Scholar 

  4. Chamberlain, J. R. & Chamberlain, J. S. Progress toward gene therapy for Duchenne muscular dystrophy. Mol. Ther. 25, 1125–1131 (2017).

    Article  CAS  Google Scholar 

  5. Mendell, J. R. et al. Brief report: dystrophin immunity in Duchenne’s muscular dystrophy. N. Engl. J. Med. 363, 1429–1437 (2010).

    Article  CAS  Google Scholar 

  6. Guiraud, S. & Davies, K. E. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 34, 36–48 (2017).

    Article  CAS  Google Scholar 

  7. Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253–261 (2002).

    Article  CAS  Google Scholar 

  8. Odom, G. L. et al. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol. Ther. 16, 1539–1545 (2008).

    Article  CAS  Google Scholar 

  9. Kennedy, T. L. et al. Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2/mdx mice. Mol. Ther. Methods Clin. Dev. 11, 92–105 (2018).

    Article  CAS  Google Scholar 

  10. Ramos, J. N. et al. Development of novel micro-dystrophins with enhanced functionality. Mol. Ther. 27, 623–635 (2019).

    Article  CAS  Google Scholar 

  11. Crudele, J. M. & Chamberlain, J. S. AAV-based gene therapies for the muscular dystrophies. Hum. Mol. Genet. https://doi.org/10.1093/hmg/ddz128 (2019).

  12. Guiraud, S. et al. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. Hum. Mol. Genet. 28, 2189–2200 (2019).

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

    Kay E. Davies

  2. University of Washington School of Medicine, Departments of Neurology, Medicine and Biochemistry, Wellstone Muscular Dystrophy Specialized Research Center, Seattle, Washington, USA

    Jeffrey S. Chamberlain

Authors
  1. Kay E. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey S. Chamberlain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kay E. Davies.

Ethics declarations

Competing interests

J.S.C. is a member of the Scientific Advisory Board for Solid Biosciences. K.E.D. has no declared conflicts.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davies, K.E., Chamberlain, J.S. Surrogate gene therapy for muscular dystrophy. Nat Med 25, 1473–1474 (2019). https://doi.org/10.1038/s41591-019-0604-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0604-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing